TRVI
Trevi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.90
+0.17%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -8.1%
- EBIT
- -15.6%
- EPS
- +20.0%
- Free cash flow
- +7.7%
- Operating cash flow
- -23.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +503.0%
- EPS
- -94.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- +10.7%
- EBIT
- +4.3%
- Net income
- +10.8%
- EPS
- +38.3%
- Free cash flow
- -10.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026